DT07 Rec'd PCT/PTO 2 3 FFR 2005

FORM PTO 1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REJ. 12-2004) ATTORNEY'S DOCKET NUMBER PP019155.0004 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE 23 August 2002 PCT/US2003/026612 25 August 2003 TITLE OF INVENTION COMPOSITIONS AND METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY EXPRESSION OF THE TUMOR-ASSOCIATED ANITGEN MN/CA IX APPLICANT(S) FOR DO/EO/US WONG, Justin WINTER, Jill LALEHZADEH, Guita and WARNE, Robert Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: Ø This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below. 4. The US has been elected (Article 31). \boxtimes A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) 5. is attached hereto (required only if not communicated by the International Bureau). b. \Box has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗆 is attached hereto. b. 🗆 has been previously submitted under 35 U.S.C. 154(d)(4). Ø Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) 7. a. 🗆 are attached hereto (required only if not communicated by the International Bureau). b. 🗆 have been communicated by the International Bureau. \boxtimes have not been made; however, the time limit for making such amendments has NOT expired. d. 🗆 have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 9. An English language translation of the annexes to the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371 (c)(5)). A copy of the International Preliminary Examination Report (PCT/IPEA/409). 11. 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. 15. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. 17. A substitute specification. 18. A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 21. \boxtimes 22. Express Mail Label No. EV351355947US \boxtimes 23. Other items or information: postcard, cheque and copy of unsigned Declaration for Patent Application

DTO1 Rec'd PCT/PTC 2 3 FEB 2005

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (tirknown see 27 TFL5) INTERNATIONAL APPLICATION NO.							ATTORNEY'S DOCKET NUMBER			
Unassigned PCT/US2003/026612							PP019155.0004			
24. The following fees are submitted:							ΑF	plicant use	Office use	
☑ a) Basic national fee							\$	\$300.00		
⊠ b) Examination fee							s	\$200.00		
⊠ c) Search fee							\$	\$500.00		
TOTAL OF ABOVE CALCULATIONS = \$1000.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding								\$1,000.00		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
Total Sheets		Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whol			RATE				
67	- 100 =	-33 /50 =		0		× \$250.00	\$	\$0.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).										
CL	CLAIMS NUMBER I		——————————————————————————————————————		RATE					
Total cla	aims	40	- 20 =	20	х	\$50.00	\$	\$1,000.00		
Indepen	dent clain	ns 5	- 3=	2	x	\$200.00	\$	\$400.00		
MULTIPLE DEPENDENT CLAIMS (if applica			(if applicable) 🗆	+	\$360.00	\$	\$0.00		
TOTAL OF ABOVE CALCULATIONS =								\$2,400.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.							\$	\$0.00		
SUBTOTAL =								\$2,400.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							\$	\$0.00		
TOTAL NATIONAL FEE =							\$	\$2,400.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$	\$0.00		
TOTAL FEES ENCLOSED =								\$2,400.00		
Amount to be refunded:									\$	
Amount to be charged:									\$	
a. 🗵 A check in the amount of \$ \$2,400.00 to cover the above fees is enclosed.										
ъ. 🗆										
с. 🛚										
d. 🔲	d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card Information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.										
SEND ALL CORRESPONDENCE TO: Risca Alexanden										
Lisa E. ALEXANDER SIGNATUR							· · · · · · · · · · · · · · · · · · ·			
CHIRON CORPORATION Lisa E. Ale							exander			
Intellectual Property R338 P.O. Box 8097						NAME				
Emeryville, CA 94662-8097 US 41,576										
Customer No. 27476										
REGISTRAT							TION NUMBER			

PATENT COOPERATION TREATY IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

International Application No.

PCT/US2003/026612

International Filing Date

25 August 2003

Priority Date Claimed

23 August 2002

Title of Invention

COMPOSITIONS AND METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY EXPRESSION OF THE TUMOR-ASSOCIATED ANITGEN MN/CA IX

Applicants for DO/EO/US:

WONG, Justin, WINTER, Jill, LALEHZADEH, Guita and WARNE, Robert

CERTIFICATE OF MAILING BY EXPRESS MAIL

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Express Mail Mailing Label No.: EV351355947US

Date of Deposit:

23 February 2005

I hereby certify that the attached Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C.371 copy of unsigned Declaration for Patent Application, copy of Published Specification, Check No. 8744 in the amount \$2400.00 and Postal Receipt Card are being deposited with the United Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R.1.10 on the date indicated above and addressed to the Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

23.

February 2005

Melodi K. Dice

CHIRON CORPORATION 4560 Horton Street Emeryville, California 94608 United States of America